Patient characteristics after a median follow-up of 36 months
| Characteristic . | Prior anti-BCMA therapy . | P value . | |
|---|---|---|---|
| No . | Yes . | ||
| n | 10 | 6 | |
| Sex, n (%) | |||
| Female | 6 (60) | 3 (50) | 1.000 |
| Male | 4 (40) | 3 (50) | |
| Age, mean (SD), y | 65.2 (6.5) | 62.5 (97) | .498 |
| ISS stage, n (%) | |||
| Stage I | 1 (10.0) | 0 (0.0) | .504 |
| Stage II | 4 (40.0) | 1 (16.7) | |
| Stage III | 3 (30.0) | 2 (33.3) | |
| Unknown | 2 (20.0) | 3 (50.0) | |
| High-risk cytogenetics, n (%) | |||
| No | 3 (30.0) | 2 (33.3) | 1.000 |
| Yes | 7 (70.0) | 4 (66.7) | |
| Prior anti-BCMA therapy, n (%) | |||
| ADC | 0 (0) | 2 (33.3) | .001 |
| CAR T cell | 0 (0) | 3 (50) | |
| BsAb | 0 (0) | 1 (16.7) | |
| Prior auto transplant, n (%) | |||
| No | 1 (10) | 0 (0) | 1.000 |
| Yes | 9 (90) | 6 (100) | |
| Prior allo transplant, n (%) | |||
| No | 10 (100) | 5 (83.3) | .790 |
| Yes | 0 (0) | 1 (16.7) | |
| Received FCARH143, n (%) | |||
| No | 2 (20) | 0 (0) | .696 |
| Yes | 8 (80) | 6 (100) | |
| PFS, mean (SD), d | 674 (275) | 117 (116) | <.001 |
| OS, mean (SD), d | 883 (327) | 302 (417) | .010 |
| Characteristic . | Prior anti-BCMA therapy . | P value . | |
|---|---|---|---|
| No . | Yes . | ||
| n | 10 | 6 | |
| Sex, n (%) | |||
| Female | 6 (60) | 3 (50) | 1.000 |
| Male | 4 (40) | 3 (50) | |
| Age, mean (SD), y | 65.2 (6.5) | 62.5 (97) | .498 |
| ISS stage, n (%) | |||
| Stage I | 1 (10.0) | 0 (0.0) | .504 |
| Stage II | 4 (40.0) | 1 (16.7) | |
| Stage III | 3 (30.0) | 2 (33.3) | |
| Unknown | 2 (20.0) | 3 (50.0) | |
| High-risk cytogenetics, n (%) | |||
| No | 3 (30.0) | 2 (33.3) | 1.000 |
| Yes | 7 (70.0) | 4 (66.7) | |
| Prior anti-BCMA therapy, n (%) | |||
| ADC | 0 (0) | 2 (33.3) | .001 |
| CAR T cell | 0 (0) | 3 (50) | |
| BsAb | 0 (0) | 1 (16.7) | |
| Prior auto transplant, n (%) | |||
| No | 1 (10) | 0 (0) | 1.000 |
| Yes | 9 (90) | 6 (100) | |
| Prior allo transplant, n (%) | |||
| No | 10 (100) | 5 (83.3) | .790 |
| Yes | 0 (0) | 1 (16.7) | |
| Received FCARH143, n (%) | |||
| No | 2 (20) | 0 (0) | .696 |
| Yes | 8 (80) | 6 (100) | |
| PFS, mean (SD), d | 674 (275) | 117 (116) | <.001 |
| OS, mean (SD), d | 883 (327) | 302 (417) | .010 |
P values are shown for Wilcoxon rank-sum test for nominal variables and Fisher exact test for categorical variables. PFS and OS are not available for 1 patient who did not receive CAR T-cell therapy due to disease progression. High-risk cytogenetics included 1q+, del(17p), t(4;14), and t(14;16).
ADC, antibody-drug conjugate; allo, allogeneic; auto, autologous; BsAb, bispecific antibody; ISS, International Staging System; OS, overall survival; SD, standard deviation.